Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

por Adès, Lionel, Girshova, Larisa, Doronin, Vadim A., Díez-Campelo, María, Valcárcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Munhoz, Eduardo Ciliao, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.
Publicado 2022

Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-...

por Marin, Anelis Maria, Wosniaki, Denise Kusma, Sanchuki, Heloisa Bruna Soligo, Munhoz, Eduardo Cilião, Nardin, Jeanine Marie, Soares, Gabriela Silva, Espinace, Dhienifer Caroline, de Holanda Farias, João Samuel, Veroneze, Bruna, Becker, Luiz Felipe, Costa, Guilherme Lima, Beltrame, Olair Carlos, de Oliveira, Jaqueline Carvalho, Cambri, Geison, Zanette, Dalila Luciola, Aoki, Mateus Nóbrega
Publicado 2023